Dependence on Tru Niagen® consumer sales
A large share of revenue is tied to one branded product family, so demand softness would affect the whole business.
- Scope
- Consumer Products
- Materiality
- high
Niagen Bioscience, Inc.
Niagen Bioscience, Inc. develops and commercializes Niagen-branded nicotinamide riboside products across consumer supplements, ingredient supply, and pharmaceutical applications. The company operates through consumer products, ingredients, and pharmaceutical-oriented research activities, with sales in the United States and select international markets.
13,1 %
64,3 %
13,4 %
+29,9 %
4.86
3.83
| % | |
|---|---|
| Consumer Products | 75% Finished dietary supplement products sold under the Tru Niagen® brand and related practitioner-facing test kits. |
| Ingredients | 22% Food-grade and pharmaceutical-grade Niagen® ingredients sold to manufacturers, outsourcing facilities, and compounding pharmacies. |
| Analytical Reference Standards and Services | 3% Natural product fine chemicals and related research services historically sold to technical and research customers. |
| Pharmaceutical Segment | 0% Research and development of a therapeutic candidate for rare advanced aging diseases, without commercial sales. |
The company sells to consumers seeking NAD+ and healthy-aging supplements, primarily through Tru Niagen® and related...
- Direct-to-consumer supplement buyersprimary
Consumers purchase Tru Niagen® through the company’s e-commerce channels for daily supplementation and healthy-aging use.
- Distribution and retail partnersprimary
Authorized resellers, marketplaces, and specialty retail partners buy finished products for broader consumer reach.
- Ingredient manufacturersprimary
Consumer-product manufacturers buy food-grade Niagen® as an input for dietary supplement and food formulations.
- 503B outsourcing facilities and compounding pharmaciessecondary
These customers buy pharmaceutical-grade Niagen® for compounding under applicable regulatory requirements.
- Healthcare practitionerssecondary
Practitioners buy NAD+ test kits and may also support patient access to Niagen Plus-related offerings.
- Research and technical customersemerging
Scientific and laboratory customers buy analytical reference standards and related research services.
The company is headquartered in the United States and generates most of its business there, especially through direct...
- •United States is the core market for consumer and ingredient sales
- •Canada is served through direct-to-consumer e-commerce
- •Select Asia-Pacific markets support international consumer distribution
- •Europe and the Middle East are served through regional partners
- •International sales depend on local regulatory feasibility and partner networks
The company’s strategy centers on expanding Tru Niagen® consumer demand while deepening ingredient adoption with...
01
Scale consumer brand demandshort-term
Tru Niagen® is the main commercial engine and supports repeat purchases and brand equity.
02
Broaden ingredient commercializationmedium-term
Ingredient sales diversify the business and leverage the same core Niagen technology across multiple end markets.
03
Expand international reachmedium-term
International partners increase addressable market size without building a full direct sales force in every country.
04
Advance pharmaceutical developmentlong-term
A successful therapeutic program could create a higher-value, patent-protected revenue stream.
The business depends heavily on consumer acceptance of Tru Niagen® and on maintaining effective marketing,...
Regulatory and compliance risk
Dietary supplements, ingredient claims, and compounding activities are subject to FDA, FTC, and local rules.
- Scope
- US and international supplement/compounding channels
- Materiality
- high
Pharmaceutical development uncertainty
Drug development requires successful R&D, regulatory approval, and patent protection before commercialization.
- Scope
- Pharmaceutical segment
- Materiality
- high
Third-party clinic and partner reputation risk
The brand can be affected by conduct at clinics or by resellers even when the company does not control operations.
- Scope
- Niagen Plus and partner channels
- Materiality
- medium
Competitive pressure
Larger wellness and ingredient companies may outspend the company on marketing, distribution, and product development.
- Scope
- Consumer supplements and ingredients
- Materiality
- high
Revenue recognition under ASC 606
Affects net sales timing and comparability across quarters
Deferred revenue and reserves
Can change reported revenue and liabilities
Intangible assets and patent-related amortization
Affects operating expense and asset carrying values
Stock-based compensation
Affects operating expense, equity, and cash flow presentation
: 29.4.2026